#France #Guerbet #Villepinte #Lipiodol #Vascular Embolization

Guerbet's Landmark Achievement in Vascular Embolization

Guerbet, a prominent player in the field of medical imaging, has recently made headlines by achieving a significant regulatory milestone with its product, Lipiodol® Ultra Fluid. This development is particularly noteworthy for its application in vascular embolization procedures, envisioned to enhance the safety and effectiveness of these interventions across various medical domains.

Regulatory Breakthrough

On April 24, 2026, Guerbet (Euronext Paris: FR0000032526 GBT) announced a positive outcome from a collaborative procedure involving several EU member states. This collaboration paves the way for a new indication for Lipiodol® in interventional radiology procedures, specifically for peripheral and central vascular embolization. This innovative approach utilizes cyanoacrylate-based surgical adhesives, which are compatible with Lipiodol Ultra Fluid. This operation not only aids in visualizing the embolization process but also allows physicians to adjust the polymerization time, consequently enhancing procedural safety and precision.

Francois Convenant, the Senior Vice President of Interventional Radiology at Guerbet, emphasized the significance of this regulatory achievement, noting that the radiopacity and physicochemical properties of Lipiodol® facilitate more controlled, predictable, and safer embolization procedures. He remarked, "This official recognition formalizes years of clinical practice and simplifies the process of standardizing embolization techniques with adhesives throughout Europe."

Advantages of Lipiodol® in Interventional Radiology

The growing reliance on embolic agents in interventional radiology underscores the need for solutions that offer precision, speed, and durability. Lipiodol® provides a liquid, radiopaque embolizing agent essential for:

• - Real-Time Visualization: The ability to visualize the embolization instantaneously during the injection leads to immediate confirmation of vascular occlusion.
• - Adjustable Viscosity and Polymerization Time: Medical professionals can tailor the embolization process for both proximal and distal vessels based on real-time conditions.
• - Permanent and Efficient Occlusion: By ensuring effective blockage, the necessity for repeat procedures is significantly reduced.

Commitment to Healthcare Professionals

Guerbet has expressed its dedication to supporting interventional radiology teams across Europe. The company’s commitment encompasses:

• - Providing robust scientific and clinical backing.
• - Developing specialized medical training programs.
• - Expanding field presence to ensure immediate support.
• - Offering reliable solutions designed to elevate care quality and patient safety while maintaining cost-effectiveness for institutions.

About Guerbet

Guerbet is a global leader in medical imaging, committed to fostering enduring relationships that improve quality of life. The company has been at the forefront of innovative imaging solutions for over a century, with a comprehensive range of pharmaceutical products, medical devices, and digital solutions, all focused on enhancing diagnostic imaging and interventional procedures. The company allocates 10% of its revenue to research and development, with operations in four centers located in France and the United States. As of 2025, Guerbet reported revenues of 786 million euros.

To learn more about Guerbet and its range of products and services, visit guerbet.com.